A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
Phase 1/2 Recruiting
80 enrolled
DART-NK-SCLC
Phase 1/2 Recruiting
60 enrolled
DUAL-OV-CAR-NK
Phase 1/2 Recruiting
36 enrolled
MK-1045-001
Phase 1 Recruiting
100 enrolled
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Phase 3 Recruiting
440 enrolled
ATLAS
Phase 1 Recruiting
30 enrolled
AB02
Phase 3 Recruiting
1,100 enrolled
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Phase 1/2 Recruiting
160 enrolled
Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sarcoma (EWS)
Phase 1 Recruiting
50 enrolled
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
Phase 1 Recruiting
453 enrolled
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
Phase 1 Recruiting
180 enrolled
A Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma
Phase 1 Recruiting
80 enrolled
SUCCESSOR-1
Phase 3 Recruiting
810 enrolled
A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL
Phase 1/2 Recruiting
281 enrolled
iMATRIX GLO
Phase 1/2 Recruiting
65 enrolled
OLYMPIA-5
Phase 3 Recruiting
470 enrolled
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
Phase 1 Recruiting
130 enrolled
A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)
Phase 1 Recruiting
120 enrolled
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
Phase 1 Recruiting
60 enrolled
MEVPRO-1
Phase 3 Recruiting
600 enrolled
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
Phase 2 Recruiting
496 enrolled
RAINFOL-03
Phase 3 Recruiting
544 enrolled
A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
Phase 1 Recruiting
30 enrolled
FourLight-3
Phase 3 Recruiting
1,020 enrolled
A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
Phase 2 Recruiting
100 enrolled
A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma
Phase 3 Recruiting
228 enrolled
Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer
Phase 1 Recruiting
70 enrolled
Study of LYL314 in Aggressive Large B-Cell Lymphoma
Phase 1/2 Recruiting
270 enrolled
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
Phase 1/2 Recruiting
166 enrolled
Lumi-NHL
Phase 1/2 Recruiting
91 enrolled
REMASTer: REcurrent Brain Metastases After SRS Trial
Phase NA Recruiting
261 enrolled
EVEREST-2
Phase 1/2 Recruiting
474 enrolled
ACTengine
Phase 1/2 Recruiting
375 enrolled
Study of Out of Specification for Tisagenlecleucel
Phase 3 Recruiting
200 enrolled
Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma
Phase 1 Recruiting
217 enrolled
AHEAD-MERIT
Phase 2/3 Recruiting
350 enrolled
LINKER-MM1
Phase 1/2 Recruiting
387 enrolled 1 FDA
TERZO
Phase 3 Recruiting
124 enrolled
QUINTESSENTIAL
Phase 2 Recruiting
230 enrolled
TITANium
Phase 1/2 Recruiting
174 enrolled
A Study of Subcutaneous Trastuzumab Deruxtecan in Participants With Metastatic Solid Tumors
Phase 1 Recruiting
76 enrolled
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
Phase 1/2 Recruiting
361 enrolled
MagnetisMM-30
Phase 1 Recruiting
87 enrolled
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK012
Phase 1 Recruiting
48 enrolled
A Study of YKST02 in Participants With Relapsed or Refractory Multiple Myeloma
Phase 1 Recruiting
70 enrolled
A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL
Phase 2 Recruiting
115 enrolled
Study to Evaluate Efficacy and Safety of HH2853 in Relapsed/Refractory Peripheral T-cell Lymphoma
Phase 1/2 Recruiting
100 enrolled
SHARON
Phase 1 Recruiting
24 enrolled
A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia
Phase 1/2 Recruiting
104 enrolled
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
Phase 1/2 Recruiting
796 enrolled